STAT Brand Studio

We strive each day to make a difference in the lives of people impacted by the devastating symptoms and effects of immune-mediated diseases. With this determination, the Johnson & Johnson Innovative Medicine team is relentless in our efforts to pioneer treatments and redefine outcomes for patients by not only imagining but leading a new era of innovation in immunology. I recently had the opportunity to highlight six principles of our ambitious approach with STAT and invite you to read about what drives us to realize this future for the millions of people and families affected by diseases of the immune system. Read the article here: https://bit.ly/4hwMLlv #MyCompany #JNJImmunology #Innovation #PatientDriven #Imagine #Future

During the annual J.P. Morgan Healthcare Conference, David Carmouche, MD, executive vice president and chief clinical transformation officer at Lumeris, spoke with STAT about the transformative role of artificial intelligence in primary care. He emphasized that AI is enabling healthcare providers to personalize patient care like never before, improving outcomes and satisfaction. Read the full article here: https://lnkd.in/ex5uy5z8 #HealthcareInnovation #ArtificialIntelligence #PrimaryCare #PatientEngagement #HealthTech

Loving the pictures from #JPM25 in the STAT Brand Studio multimedia lounge! So many fantastic conversations, podcasts and recordings in the STAT co-working space with sponsors, executives, and more. Photo credit Sarah Gonzalez + STAT Brand Studio with CG Life, David Ormesher, Chris Peetz, R. Casey Boutwell, PhD, MBA, David Carmouche, MD & Bruce Leuchter, M.D.

STAT Brand Studio multimedia lounge and editor Jesse McQuarters are back at #JPM25 in the stunning STAT co-working space! Looking forward to interviews with CG Life, Genentech, Mirum Pharmaceuticals, Inc., Lumeris, Cencora, and others. Hope to see you there!

Biotherapeutic discovery often comes with a low margin of success — only about 10% of drug candidates make it to market, and it can take 10-15 years to prove efficacy. But what if the process could be sped up and scaled? Genentech is harnessing the power of #AI to assist scientists, and changing the traditional, sequential model of drug discovery to one that is cyclical and iterative.

The #biopharma industry is developing unique #multimodal therapeutics that push the boundaries of what we once thought was clinically possible. Cytiva's chief scientific officer Daria Donati provided insight into #ATMPs and #genomic #medicine during this recent STAT Brand Studio event. https://lnkd.in/gfzFNg35

Dr. Joan Cangiarella — Elaine Langone Professor of Pathology at the NYU Grossman School of Medicine and Senior Associate Dean for Education, Faculty, and Academic Affairs at NYU Langone Health — talks about how Langone’s tuition-free model is changing medical education. “It takes a long time and it takes a lot of money to go to medical school. And I think the ability to offer tuition-free allows you to get the best applicants,” says Dr. Cangiarella. Hear more insights in a STAT Brand Studio discussion: https://lnkd.in/gmnh8TF7

In this STAT Brand Studio podcast, Dr. Joan Cangiarella — Elaine Langone Professor of Pathology at the NYU Grossman School of Medicine and Senior Associate Dean for Education, Faculty, and Academic Affairs at NYU Langone Health — explains what inspired a bold departure from traditional medical education. https://lnkd.in/gmnh8TF7

You can now watch our STAT Brand Studio event 'Clinical Potential of Multimodal Therapeutics' on demand! The #biopharmaceutical industry is working to develop unique multimodal therapeutics that push the boundaries of what is clinically possible. Learn how with speakers from Pioneering Medicines, Aldevron and Cytiva. Watch: https://trib.al/g7nBGwt

As the clinical pipeline expands, researchers are testing mechanisms from across the drug landscape in combination to deliver innovative treatments. Join us tomorrow to explore how the biopharmaceutical industry is taking an outcome-based approach to developing unique multimodal therapeutics that push the boundaries of what we once thought was clinically possible. Jesse McQuarters - moderator Palani Palaniappan - Chief Technology Officer, Pioneering Medicines Michael Chambers - Co-Founder and Chairman, Aldevron Daria Donati - Chief Scientific Officer, Genomic Medicine, Cytiva Iwan Roberts - VP, Technology and Innovation Strategy, Cytiva Registration: https://lnkd.in/gfzFNg35